Macdougall Jessica D, Burks A Wesley, Kim Edwin H
Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Immunotargets Ther. 2021 Jan 27;10:1-8. doi: 10.2147/ITT.S266257. eCollection 2021.
In the last decade, there has been increasing research dedicated to food immunotherapy to induce clinical desensitization and provide protection by increasing clinical reaction thresholds. Results from recent food immunotherapy studies with differing routes of administration (oral, sublingual, and epicutaneous) suggest that food immunotherapy can induce clinical desensitization with varying levels of safety, however lasting tolerance has not been demonstrated. Furthermore, treatment side effects and dosing logistics may make the therapies difficult for some supporting the need for alternative treatment approaches. Peptide immunotherapy and DNA vaccine approaches should in theory allow for safer administration by decreasing allergenicity but proof of their clinical efficacy and immunogenicity remains to be proven. Biologic agents may allow for increased safety and rapid up-dosing of immunotherapy with the added benefit of treating multiple allergens simultaneously.
在过去十年中,致力于食物免疫疗法以诱导临床脱敏并通过提高临床反应阈值提供保护的研究不断增加。近期不同给药途径(口服、舌下和经皮)的食物免疫疗法研究结果表明,食物免疫疗法可诱导临床脱敏,安全性各异,但尚未证明能产生持久耐受性。此外,治疗副作用和给药安排可能使某些疗法实施困难,这支持了对替代治疗方法的需求。肽免疫疗法和DNA疫苗方法理论上应通过降低变应原性实现更安全的给药,但它们的临床疗效和免疫原性仍有待证实。生物制剂可能会提高免疫疗法的安全性并实现快速加量给药,同时还具有能同时治疗多种过敏原的额外优势。